



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund
Medicines Recommended by NICE and AWMSG
Health Board Formulary Status
(From 01 January 2024 to 31 December 2024)



BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable, and certainly within 60 calendar days of the publication of the decision. Commencement of the 60 days is the date known as the 'NTF start date'. For National Institute for Health and Care Excellence (NICE) recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD)/Final Draft Guideline (FDG), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For All Wales Medicines Strategy Group (AWMSG) recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60-day timescale may be delayed. In such circumstances the 'NTF start date' aligns with the date that the delaying reason has been resolved. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, The New Treatment Fund – Access to medicines recommended by NICE and AWMSG (WHC [2017] 001). From May 2024 these directions are further revised to enable the granting, in specific circumstances, of an extension to the standard 60-day timescale. This is detailed at:- <https://www.gov.wales/directions-new-treatment-fund-exemptions>.

A formulary is an official list of medicines which may be prescribed within the health board or NHS trust to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use. Velindre University NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended over a 12-month period, commencing at least 14 months prior to the publication of this report. This is to account for the generally applicable 60-day period available to health boards and NHS trust to add these medicines to their formularies. Where an extended timescale has been authorised the data reporting system has been adapted to accommodate the variations.

SOURCE OF INFORMATION

This report has been compiled through an analysis of health board and trust submitted data to the All Wales Therapeutics and Toxicology Centre (AWTTC).

In exceptional circumstances some medicines data have been removed from this report in light of specific factors outside the control of health boards and NHS trust.

Data extracted 12/05/2025






Key		On formulary within required timescale		On formulary outside of required timescale		Not on formulary but within required timescale
		Not on formulary and outside of required timescale		Not applicable to Velindre		

Table 1. Formulary status for New Treatment Fund medicines

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID3920 (TA951)	Abiraterone	Prostate cancer	09 Jan 24								
ID3920 (TA951)	Olaparib	Prostate cancer	09 Jan 24								
ID1342 (TA952)	Talazoparib	Breast cancer	19 Jan 24								
ID6262 (TA878)	Nirmatrelvir/ritonavir	COVID-19	26 Jan 24								
ID4045 (TA954)	Epcoritamab	B-cell lymphoma	01 Feb 24								
ID6307 (TA953)	Fluocinolone acetonide	Chronic diabetic macular oedema	20 Feb 24								
ID1688 (TA950)	Nivolumab-relatlimab	Melanoma	21 Feb 24								
ID4007 (TA958)	Ritlecitinib	Alopecia areata	22 Feb 24								
ID3938 (TA924)	Tirzepatide	Type 2 diabetes	23 Feb 24								
ID3748 (TA959)	Daratumumab	Amyloidosis	28 Feb 24								
ID6191 (TA962)	Olaparib	Ovarian, fallopian tube or peritoneal cancer	28 Feb 24								
ID3876 (TA934)	Foslevodopa-foscarbidopa	Parkinson's disease	29 Feb 24								
ID6184 (TA964)	Cabozantinib	Renal cell carcinoma	11 Mar 24								
ID6184 (TA964)	Nivolumab	Renal cell carcinoma	11 Mar 24								
ID3968 (TA963)	Dostarlimab	Endometrial cancer	14 Mar 24								
ID6141(TA957)	Momelotinib	Myelofibrosis-related splenomegaly	14 Mar 24								
ID5084 (TA967)	Pembrolizumab	Hodgkin lymphoma	21 Mar 24								
ID5091 (TA956)	Etrasimod	Ulcerative colitis	05 Apr 24								
ID6261 (TA971)	Remdesivir	COVID-19	09 Apr 24								
ID1434 (TA937)	Budesonide	IgA nephropathy	10 Apr 24								
ID5090 (TA973)	Atogepant	Migraine	11 Apr 24								
ID6290 (TA975)	Tisagenlecleucel	Leukaemia	11 Apr 24								
ID6193 (TA970)	Selinexor	Multiple myeloma	18 Apr 24								
ID3797 (TA974)	Selinexor	Multiple myeloma	22 Apr 24								
ID3947 (HST31)	Setmelanotide	Bardet-Biedl syndrome	22 Apr 24								
3153	Trifarotene	Acne Vulgaris	29 Apr 24								
ID6164 (TA948)	Ivosidenib	Cholangiocarcinoma	08 May 24								
ID6198 (TA979)	Azacitidine	Leukaemia	10 May 24								
ID6198 (TA979)	Ivosidenib	Leukaemia	10 May 24								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morganwg	Hywel Dda	Powys	Swansea Bay	Velindre
5285	Opicapone	Parkinson's disease	17 May 24								
17	Alglucosidase alfa	Pompe disease	20 May 24								
ID6327 (TA984)	Tafamidis	Amyloidosis	30 May 24								
ID3834 (TA988)	Ivacaftor-tezacaftor-elexacafto..	Cystic fibrosis	20 Jun 24								
ID3834 (TA988)	Lumacaftor-ivacaftor	Cystic fibrosis	20 Jun 24								
ID3834 (TA988)	Tezacaftor-ivacaftor + ivacaftor	Cystic fibrosis	20 Jun 24								
ID4025 (TA986)	Lebrikizumab	Atopic dermatitis	21 Jun 24								
ID5104 (TA977)	Dabrafenib	Glioma	03 Jul 24								
ID5104 (TA977)	Trametinib	Glioma	03 Jul 24								
3708	Cytisinicline (cytisine)	Smoking cessation	10 Jul 24								
ID6187 (TA995)	Relugolix	Prostate cancer	19 Jul 24								
ID4030 (TA997)	Pembrolizumab	Gastric or gastro-oesophageal junction adenocarcinoma	26 Jul 24								
ID1363 (TA1009)	Latanoprost-netarsudil	Glaucoma or ocular hypertension	01 Aug 24								
ID2704 (TA1002)	Evinacumab	Homozygous familial hypercholesterolaemia	08 Aug 24								
ID6197 (TA1004)	Faricimab	Visual impairment	08 Aug 24								
ID6300 (TA999)	Vibegron	Overactive bladder	08 Aug 24								
ID6306 (TA990)	Tenecteplase	Acute ischaemic stroke	13 Aug 24								
ID5085 (TA1001)	Zanubrutinib	Lymphoma	15 Aug 24								
ID6209 (TA998)	Risankizumab	Ulcerative colitis	27 Aug 24								
ID6298 (TA1008)	Bevacizumab	Colorectal cancer	28 Aug 24								
ID6298 (TA1008)	Trifluridine-tipiracil	Colorectal cancer	28 Aug 24								
ID6176 (TA1000)	Iptacopan	Paroxysmal nocturnal haemoglobinuria	04 Sept 24								
ID882 (TA991)	Abaloparatide	Osteoporosis	04 Sept 24								
ID6132 (TA1039)	Selpercatinib	Thyroid cancer	06 Sept 24								
ID4042 (TA1013)	Quizartinib	Acute myeloid leukaemia	19 Sept 24								
ID6288 (TA1038)	Selpercatinib	Thyroid cancer	26 Sept 24								
ID3770	Avapritinib	Mastocytosis	03 Oct 24								
155	Galsulfase	Mucopolysaccharidosis	09 Oct 24								
371	Miglustat	Niemann-Pick type C disease	09 Oct 24								
ID6333 (TA1015)	Teclistamab	Multiple myeloma	10 Oct 24								
ID6190 (TA996)	Linzagolix	Uterine fibroids	14 Oct 24								
ID5094 (TA1017)	Pembrolizumab	Lung cancer	16 Oct 24								
ID6368 (TA1014)	Alectinib	Lung cancer	16 Oct 24								
ID5115 (TA1018)	Fedratinib	Disease-related splenomegaly or symptoms in myelofibrosis	17 Oct 24								
ID6331 (TA1016)	Elafibranor	Primary biliary cholangitis	22 Oct 24								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID4026 (TA1023)	Elranatamab	Multiple myeloma	29 Oct 24	Yellow	Green	Green	Green	Green	Green	Green	Grey
ID6289 (TA1021)	Crizotinib	Lung cancer	31 Oct 24	Green	Green	Green	Green	Green	Green	Green	Green
ID5088 (TA1010)	Danicopan	Extravascular haemolysis	04 Nov 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID6140 (TA1019)	Crovalimab	Paroxysmal nocturnal haemoglobinuria	04 Nov 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID6337 (TA1020)	Eplontersen	Transthyretin-related amyloidosis	27 Nov 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID3932 (TA1011)	Belzutifan	Tumours associated with von Hippel-Lindau disease	28 Nov 24	Green	Green	Green	Green	Green	Green	Green	Green
ID1441 (TA1027)	Tebentafusp	Uveal melanoma	03 Dec 24	Green	Green	Yellow	Green	Green	Green	Green	Yellow
ID6350 (TA1025)	Ublituximab	Multiple sclerosis	10 Dec 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID6220 (TA1030)	Durvalumab	Lung cancer	11 Dec 24	Green	Green	Yellow	Green	Green	Green	Green	Yellow
ID3821 (TA1035)	Vadadustat	Symptomatic anaemia	12 Dec 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID3812 (TA989)	Etranacogene dezaparvovec	Haemophilia B	13 Dec 24	Green	Green	Green	Green	Green	Green	Green	Grey
ID3907 (TA1037)	Pembrolizumab	Lung cancer	20 Dec 24	Green	Green	Yellow	Green	Green	Green	Green	Yellow

End of Report

